| Drug General Information |
| Drug ID |
D03ZZH
|
| Former ID |
DCL000989
|
| Drug Name |
SLV-313
|
| Synonyms |
L001624
|
| Drug Type |
Small molecular drug
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Discontinued in Phase 1 |
[1]
|
|---|
| Company |
Solvay Pharma
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C24H24FN3O2
|
| Canonical SMILES |
C1CN(CCN1CC2=CN=CC(=C2)C3=CC=C(C=C3)F)C4=C5C(=CC=C4)OCC<br />O5
|
| InChI |
1S/C24H24FN3O2/c25-21-6-4-19(5-7-21)20-14-18(15-26-16-20)17-27-8-10-28(11-9-27)22-2-1-3-23-24(22)30-13-12-29-23/h1-7,14-16H,8-13,17H2
|
| InChIKey |
IUVSEUFHPNITEQ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14855050, 24173827, 45634476, 76821280, 85210206, 103506281, 134222285, 134339421, 135261564, 137263399, 139975857, 152258604, 160647438, 186007042, 198988441, 226973342, 242986165, 252477524
|
| Target and Pathway |
| Target(s) |
5-hydroxytryptamine 1A receptor |
Target Info |
Modulator |
|
|---|
| D(2) dopamine receptor |
Target Info |
Modulator |
|
|
KEGG Pathway
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Serotonergic synapsehsa04015:Rap1 signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Serotonin receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Serotonin HTR1 Group and FOS Pathway
|
|
SIDS Susceptibility Pathways
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. |
|---|
